Discover 529 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 529
FeaturedActive & Responsive
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
for
ALK Fusion-positive Solid or CNS Tumors
Location: Memphis TN, Cincinnati OH, Ann Arbor MI,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0 - 17
Code: NCT04774718
Phase1, Phase2, Recruiting
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for
Parkinson's Disease
Location: Memphis TN, Nashville TN, Birmingham AL, St Louis MO,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07174310
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Memphis TN, St Louis MO, Columbia MO, Warrenville IL,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT04302025
Phase2, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Memphis TN, St Louis MO, Newnan GA, Atlanta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06793215
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
for
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer,
Location: Germantown TN, Charlotte NC, Philadelphia PA, Boston MA,
Sponsor: Hoffmann-La Roche
Sex: Female
Age: 18+
Code: NCT04802759
Phase1, Phase2, Recruiting
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive